At the conclusion of this activity, participants will be able to:
1. Describe the various clinical phenotypes of inflammatory arthritis due to checkpoint inhibitor therapy.
2. Delineate ways in which immune checkpoint inhibitor-induced inflammatory arthritis can serve as a model of autoimmune arthritis
3. Discuss critical practice points for ICI-arthritis management
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation